Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection

The RNA interference (RNAi) drug ARC-520 was shown to be effective in reducing serum hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HBeAg-positive patients treated with a single dose of ARC-520 and daily nucleosidic analogue (entecavir). To prov...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadelka, Sarah, Dahari, Harel, Ciupe, Stanca M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794570/
https://www.ncbi.nlm.nih.gov/pubmed/33420293
http://dx.doi.org/10.1038/s41598-020-80594-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794570/
https://www.ncbi.nlm.nih.gov/pubmed/33420293
http://dx.doi.org/10.1038/s41598-020-80594-6

Ejemplares similares